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BAFFa b s t r a c t
Mesenchymal stem cells (MSCs) can be polarized into two distinct populations, MSC1 and MSC2, by acti-
vation of different Toll-like receptors (TLRs). TLR4-primed MSC1 expressed proinﬂammatory factors,
whereas TLR3-primed MSC2 expressed suppressive factors. However, little is known about the function
of TLRs on B lymphocyte-related immune modulation. In this study, we investigated the expression of B
cell activating factor (BAFF), a member of the tumor necrosis factor ligand superfamily with notable
stimulating activity on B cells, in human MSCs (hMSCs) and in murine MSCs (mMSCs) after activation
of TLRs. BAFF was increasingly expressed in presence of TLR4 agonist (lipopolysaccharide, LPS), while
TLR2 agonist (Zymosan) and TLR3-agonist (polyinocinic–polycytidykic acid, poly I:C) had no effect on
BAFF expression. In addition, we demonstrated that signaling pathways of NF-jB, p38 MAPK, and JNK
were involved in TLR4-primed BAFF expression. Our results suggested that TLR4 and downstream path-
ways in MSCs exert an important function in B lymphocyte-related immune regulation. Further deﬁning a
homogeneous population of MSCs should provide insight into MSC-based immune-modulating therapy.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction adenosine and Notch signaling [11] have been reported to be crit-Bone marrow (BM) mesenchymal stem cells (MSCs) are multi-
potent non-hematopoietic stem cells that can differentiate into
BM stromal cells, osteoblasts, adipocytes, chondrocytes, tenocytes,
skeletal myocytes, neurons, and cells of visceral mesoderm [1].
MSCs have been studied for their immune-suppressive effect and
have potentials for clinical applications, such as treating immune
disorders. The immune-suppressive effect of MSCs is mediated by
the secretion of soluble factors and by cell–cell contact-dependent
regulation. After stimulated by IFN-c, TNF-a and agonist Toll-like
receptor 3 (TLR3), MSCs were able to produce indoleamine
2,3-dioxygenase (IDO) [2,3], prostaglandin E2 (PGE2) [4,5], tumor
necrosis factor alpha stimulated gene-6 (TSG-6) [6], and nitricoxide
(NO) [7] to inhibit T lymphocytes. Cell–cell contact-dependent
mechanisms, including FAS/FASL [8], programmed death-1/
programmed death ligand-1 [9], galectins [10], CD39-inducedical in MSC-related immune modulation.
TLRs play an important role in MSC-mediated immune-regula-
tory functions. They are recognized as a wide variety of
pathogen-associated molecular patterns (PAMP) in bacteria,
viruses, fungi, and some host-derived molecules [12]. Thirteen
mammalian TLR analogs, including 10 in humans and 13 in mice,
have been identiﬁed. TLR 1-6 are expressed at a higher level
in adipose-derived mesenchymal stem cells (AD-MSCs) and
BM-MSCs in humans and in mice [13]. Among them, the agonists
of TLR3 and TLR4 in human MSCs (hMSCs) induce down-
regulation of the of Notch ligand Jagged-1, and thus decrease
the ability of MSCs to suppress allogeneic T cell proliferation
[14]. In murine MSCs (mMSCs), an activation of TLR2 and TLR4
increased IL-6 secretion via NF-jB pathway [15]. On the other
hand, TLR agonists-activated MSCs are able to increase B lympho-
cytes proliferation [16] and switch IgG production [17,18],
suggesting a critical role in progression of B lymphocytes-relating
immune disorders.
B cell-activating factor, BAFF, is a vital survival factor that
supports generation, differentiation, maturation of B lymphocytes
to maintain a functional B lymphocyte pool [18]. We previously
reported that adipocytic differentiation of mMSCs promotes B
lymphocytes proliferation by secretion of BAFF [19]. However,
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major function on BAFF secretion in MSCs.
In this study, we investigated the effect of TLR priming on BAFF
expression in mMSCs and in hMSCs. We found that BAFF in hMSCs
or in mMSCs was expressed at a higher level after TLR4-priming,
indicating that TLR4 and a downstream pathway play a role in
BAFF secretion and thus exert an important function in B
lymphocyte-related immune regulation.
2. Materials and methods
2.1. Culture and differentiation of MSCs from human and mouse
Healthy human bone marrow samples were collected from
eight patients (33–55 years old) from Huashan Hospital, Fudan
University, who had subscribed a consent form. The patients were
diagnosed as NK/T nasal lymphoma, hypersplenism, whose bone
marrow examination excluded inﬁltration of malignant cells and
other abnormalities. Human BM-MSCs were puriﬁed by the Percoll
density gradient centrifugation method and were cultured in
Dulbecco’s modiﬁed Eagle’s medium containing 4.0 mM of glucose
(DMEM-LG, Hyclone, Beijing, China) supplemented with 10% fetal
bovine serum (FBS, Hyclone, Beijing, China), 100 U/ml penicillin,
and 100 U/ml streptomycin (Hyclone, Beijing, China), in a
humidiﬁed atmosphere of 5% CO2.
BALB/c mice at 6–8 weeks of age were purchased from the Slack
Animal Center of Science Academy of China (Shanghai, China). All
animals were bred and maintained under speciﬁc pathogen free
conditions. Murine BM cells were ﬂushed out of the tibia and
femur by phosphate-buffered saline (PBS). The cells were
incubated at 37 C in a humidiﬁed atmosphere with 5% CO2 for
3 days to allow attachment of adherent cells. Thereafter, medium
was changed every other day. Passages were performed when cells
obtained 80% conﬂuence. After three passages, phenotype and
differentiation assays were performed as previous report [19]
and the cells were used for further experiments.
To stimulate adipogenic differentiation, MSCs were cultured in
the adipogenic medium, DMEM-LG containing 10% FBS, 107 mol/
l dexamethasone (Sigma), 50 mg/ml indomethacin (Sigma),
0.5 mM of 3-isobutyl-L-methyl-xanthine (Sigma), and 0.01 mg/ml
of insulin (Sigma) for 14 days. Adipogenesis was detected by oil
red O staining, and was conﬁrmed by phase contrast microscopic
observation.
To stimulate osteogenesis, 108 mM dexamethasone, 0.2 mM
ascorbic acid-2-phosphate, and 10 mM beta-glycerophosphate
were added into the basic medium, and the medium was changed
twice weekly. Alkaline phosphatase (ALP) expression was exam-
ined at day 21. ALP staining was carried out using an ALP kit
according to the manufacturer’s instructions (Beyotime).
2.2. Flow cytometry analysis
Murine and human MSCs were harvested and analyzed by ﬂow
cytometry with a BD-FACS Calibur ﬂow cytometer (BD Biosciences,
San Jose, CA). Murine MSCs were stained with ﬂuorescein isothio-
cyanate (FITC)-conjugated anti-CD44, CD31, CD45, Scal-1 (stem
cell antigen-1), phycoerythrin (PE)-conjugated anti-CD106 and
APC-conjugated anti-CD34. Human MSCs were stained with
FITC-conjugated anti-CD44, CD31, CD45, CD90, PE-conjugated
anti-CD105, CD34, and APC-conjugated anti-CD90 (all from Bioleg-
end, San Diego, CA, USA).
2.3. TLR priming
Zymosan (1 mg/ml, Sigma–Aldrich, MO), polyinocinic–
polycytidykic acid (Poly(I:C), 1 mg/ml , InvivoGen, CA) andlipopolysaccharide (LPS, Sigma–Aldrich, MO) were used as the ago-
nists for TLR2, TLR3 and TLR4, respectively. TLR-agonists were
added to fresh growth medium and incubated with the cells for
48 h.
2.4. Real-time quantitative PCR analysis
Total RNA of mMSCs or hMSCs was isolated by Trizol reagent
(invitrogen) according to the manufacturer’s instructions. Ampliﬁ-
cation and detection of speciﬁc products were carried out in a
StepOnePlus™ Real-Time PCR System (Life Technologies). Speciﬁc
primers were used to amplify cDNA, for murine BAFF (50-ACGGA-
GACGACACCTTCTTT-30; 50-GGCTTTCCCCATCTTTTAGTT-30) and for
human BAFF (50-CAATCCAATCGGAGGGTA-30; 50-TGTTTGTTGATG
TCCTGC-30).
2.5. Blocking of TLR2 and TLR4
MSCs were seeded in basic medium in 6-well plates at a
concentration of 3  104/cm2, the medium was then added with
2 lg/ml of anti-TLR2 (functional grade puriﬁed, MTS510), anti-
TLR4 (functional grade puriﬁed, 6C2) or isotype control antibody
(all purchased from eBioscience) respectively for 30 min at 37 C.
2.6. Western blotting analysis of BAFF expression
Western blot analysis was executed as the previous report [19].
Immunoreactivity was detected using the ImageQuant LAS
4000 mini (GE). Antibody against BAFF was purchased from
Sigma–Aldrich (St. Louis, MO, USA). Antibody against b-Actin was
purchased from Santa Cruz (San Diego, CA, USA). The results were
analyzed using ImageJ software.
2.7. Immunocytochemistry analysis of NF-jB nuclear translocation
in mMSCs
Murine MSCs were seeded on the slides, and stimulated by LPS
for 4 h. The cells were ﬁxed, permeabilized, and then incubated
with the primary antibody to NF-jB (Cell Signaling Technology,
Danvers, MA) overnight. The secondary antibody conjugated with
Dylight was counterstained for 30 min at 37 C. The slides were
examined after stained with 6-diamidino-2-phenylindole (DAPI)
and photographed using a confocal microscope (TCS SP5 AOBS,
Leica Microsystems CMS GmbH, Mannheim, Germany).
2.8. Statistical analysis
Data were represented as mean ± SD. Multiple group compari-
sons were performed by one-way analysis of variance (ANOVA)
followed by the Bonferroni procedure for comparison of means.
Comparison between any two groups was analyzed by the
two-tailed Student’s t-test with GraphPad Prism4 Software. Values
of p < 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Characterization and differentiation of MSCs
Non-hematopoietic BM stromal cells were separated based on
plastic adhesion, and characterized by immunophenotypes and
their differentiation potential. Murine MSCs were negative for
CD45, CD31, or CD34, but mild positive for CD106 and strong
positive for Sca-1 and CD44 (Fig. 1A). While humanMSCs were also
negative for CD45, CD31, or CD34, they were positive for CD105,
CD90, and CD44 (Fig. 1B). The adherent cells grew as a spindle-
shaped ﬁbroblastic morphology after 2–3 passages. To determine
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osteogenic and adipogenic lineages. After culturing in osteogenic
induction medium for 3 weeks, the cells became positive for
Alkaline Phosphatase staining, indicating that our cultured MSCs
had osteogenic differentiation potential (Fig. 1C). The adipogenic
differentiation of MSCs was conﬁrmed by oil red O staining after
induction in adipogenic medium for 14 days (Fig. 1C). These data
suggested that the cultured BM stromal cells possessed typical
characteristics of MSCs.
Investigations on the effect of TLR activation onMSC differentia-
tion raise a controversial issue, in which one report indicated that
priming of TLR3 and TLR4 promotes the osteoblast differentiation
[20], while the other report indicated that TLR2 activation decreases
the multi-lineage differentiation capability of mMSCs [21]. To
investigate the effects of TLR2 and TLR4 on mMSC differentiation,
we induced MSC differentiation in presence of TLR2 agonist,
zymosan (1 lg/mL), and TLR4 agonist, LPS (1 lg/ml), respectively.
With the treatment of LPS or zymosan, the cells were positively
stained oil red O and Alkaline Phosphatase, indicating that mMSCs
retained their potential to differentiate into osteoclasts and
adipocytes when TLR2 and TLR4 were activated (Fig. 1D and E).
3.2. TLR4 activation increased BAFF production inmMSCs and in hMSCs
To investigate whether TLR stimulation alters BAFF expression
in MSCs, the expression of BAFF in mMSCs in response to differentFig. 1. Characterization of BM-MSCs. Immunophenotype of bone marrow-derived MSCs f
showed a spindle-shaped ﬁbroblastic morphology, Scale bar = 100 lm. (D) For osteog
bar = 100 lm. For adipogenic induction, the accumulated lipid vacuoles were stained w
presence of agonists of TLR2 or TLR4 for two weeks, and were stained by alkaline phospconcentration of LPS was determined by real-time PCR analysis.
BAFF expression was increased in a dose-dependent manner and
peaked at the concentration of 1 lg/ml LPS (Fig. 2A). Compared
with the result of TLR2 stimulation by 1 lg/ml zymosan, TLR4-
activation increased BAFF expression by 2–3 folds, whereas TLR2-
activation increased BAFF expression modestly (Fig. 2B and C).
To determine whether the agonists of TLRs inﬂuence the BAFF
expression in hMSCs, hMSCs were treated with TLR2 agonist
(zymosan), TLR3 agonist (poly(I:C)), or TLR4 agonist (LPS) for
48 h. BAFF expression in TLR4-stimulated hMSCs, at mRNA level
and at protein level, was higher than that in TLR2-stimulated and
TLR3-stimulated hMSCs (Fig. 2D and E). Taken together, these
results indicated that an activation of TLR4, rather than TLR2 or
TLR3, increased BAFF expression.3.3. Blockade of TLR4 decreased BAFF expression
To further elucidate whether TLRs inﬂuence BAFF expression in
a direct or indirect way, mMSCs were treated with anti-TLR4 or
anti-TLR2 mAb to block the receptors before addition of LPS or
zymosan. After the blockage of TLR4, BAFF expression was
decreased by 53.2 ± 12.2% (p < 0.05), whereas TLR2 blockage only
decreased BAFF expression by 23.5 ± 19.1% that had no signiﬁcant
difference compared to addition of zymosan only (Fig. 3). This
indicated that TLR4, but not TLR2, regulated BAFF expression.rommice (A) and humans (B) were analyzed by ﬂow cytometry. (C) Cultured mMSCs
enic induction, the cells were stained for alkaline phosphatase at day 21. Scale
ith oil red O at day 14. Scale bar = 100 lm. (E) Murine MSCs were differentiated in
hatase and oil red O (n = 3).
Fig. 2. TLR4-activation increased BAFF production in mMSCs and in hMSCs. (A) Murine MSCs were treated with LPS at the concentration of 0.1 lg/ml, 0.5 lg/ml, 1 lg/ml,
5 lg/ml, and 10 lg/ml for 48 h. The expression of BAFF was determined by real-time RT-PCR. (B) Murine MSCs were stimulated with zymosan (1 lg/ml) or LPS (1 lg/ml) for
48 h. The expression of BAFF was determined by real-time RT-PCR. (C) The BAFF protein expression in mMSCs was detected by western blot, and analyzed by ImageJ software.
(D) Human MSC was stimulated with zymosan (1 lg/ml), poly(I:C) (1 lg/ml) or LPS (1 lg/ml) for 48 h. The expression of BAFF was determined by real-time RT-PCR. (E) The
BAFF protein expression in hMSCs was detected by western blot, and analyzed by ImageJ software. Data were presented as the mean ± SD, and were compared to the control
(⁄p < 0.05, n = 5).
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It had been reported that NF-jB, JNK and p38 MAPK are related
to TLRs and their downstream signaling pathways to trigger induc-
tion and secretion of various cytokines, chemokines and other
inﬂammatory mediators. To determine whether NF-jB, JNK and
p38 MAPK were involved in TLR4-related BAFF expression, speciﬁc
inhibitors to NF-jB pathway (pyrrolidinedithiocarbamic acid,
PDTC), JNK pathway (SP600125) and p38 MAPK pathway
(SB203580) were added into cultured media of mMSCs before
LPS stimulation. An addition of PDTC, SP600125 or SB203580
decreased BAFF expression by 90.4 ± 2.4%, 87.0 ± 7.2% and97.9 ± 4.8%, respectively (p < 0.05) (Fig. 4A), indicating that these
signaling pathways were involved in TLR4-regulated BAFF expres-
sion. In addition, we showed that NF-jB translocated into the
nuclear after LPS stimulation by immunoﬂuorescence analysis of
NF-jB. The speciﬁc inhibitor to NF-jB signaling, PDTC, abrogated
the p-NF-jB p65 transloaction (Fig. 4B).
4. Discussion
Two homogenous phenotypes of MSCs, MSC1 and MSC2, have
been classiﬁed recently. The polarization of MSC1 or MSC2
depends on priming of TLRs on MSC surface [22]. After TLR3
activation, MSCs are induced into MSC2 phenotype and produce
Fig. 3. Blockade of TLR4 decreased the BAFF expression. Murine MSCs were treated
with anti-TLR2 or anti-TLR4 antibodies for 30 min at 37 C before stimulated with
zymosan or LPS, respectively. After cultured in presence of anti-TLR2 + zymosan or
anti-TLR4 + LPS for 48 h, BAFF expression was determined by real-time RT-PCR.
Data were presented as the mean ± SD, and were compared to the isotype control
(⁄p < 0.05, n = 5).
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cyte growth factor (HGF) and hemoxygenase (HO), to suppress T
cell proliferation and favor proliferation of regulatory T cells
(Tregs) [22]. However, the activation of TLR4 polarizes MSCs into
a proinﬂammatory MSC1 phenotype to secret chemokines,
including MIP-1a and MIP-1b, RANTES, CXCL9 and CXCL10, that
recruit lymphocytes to the sites of inﬂammation and enhance T
cell-mediated immune responses [23].
In addition, some sub-populations of MSCs have been charac-
terized to respond differently to TLRs. For example, Nestin+ MSCs
respond to TLR4-activation by secretion of monocyte chemotactic
protein-1 (MCP1) that promotes neutrophil migrating into tissues
[24]. However, little is known about the relation of TLRs to B
cell-mediated immune modulation.
BAFF has been proved to be a critical factor for the proliferation
of B lymphocytes. In our previous study, we found that MSCs
underwent adipogenic differentiation not only stimulate T
lymphocytes, but also enhance B-lymphocyte proliferation by
secreting BAFF [19]. In this study, we distinguished MSC
sub-population types in BAFF expression to assess the effect of
MSCs on immune modulating properties resulted from their
heterogeneity. It had been demonstrated that TLR2, TLR3 and
TLR4 are expressed at a higher level in hMSC [15], and TLR1-8 isFig. 4. NF-jB, JNK and p38 MAPK pathways were involved in the regulation of TLR4-re
inhibitor), SP600125 (a JNK inhibitor), or SB203580 (a p38 MAPK inhibitor) at the conce
48 h. The expression of BAFF was determined by real-time RT-PCR. Data were presented
n = 5). (B) NF-jB nuclear translocation was analyzed by immunoﬂuorescence on untrea
with PDTC and LPS for 4 h (right), scale bar = 15 lm.expressed at a higher level in mMSCs [21]. TLR2 and TLR4 have
been proved to affect the immune-modulation effects of mMSCs,
whereas other TLRs have no effect on the immune-modulation
functions of MSCs [25]. Therefore, we investigated the effects of
TLR2, TLR3 and TLR4 on BAFF expression. Our data showed that
TLR4-priming in hMSCs and in mMSCs increased BAFF expression,
whereas a stimulation of TLR2 or TLR3 had no effect on BAFF
expression. Our study of TLR blockage also indicated that TLR4-
priming, rather than TLR2- or TLR3-priming, played an important
role in BAFF expression, and thus regulated B-lymphocyte
proliferation.
MSCs have been used for the treatment of graft-versus-host dis-
ease (GVHD) and other autoimmune diseases based on their
immune-suppressive function [26]. Speciﬁc biomarkers of MSCs
regarding the efﬁcacy of treatment are different. TLR3-primed
MSCs give rise to MSC2 phonotype, which produces anti-inﬂam-
matory factors, but not pro-inﬂammatory, and which has a
potential in immune-suppressive treatment [22].
Compared to immune-suppressive functions of MSCs, the proin-
ﬂammatory functions of MSCs are not extensively investigated and
the results are often contradictory. An activation of TLR2 increases
IL-6 production and the number of CD4+ T cells, promoting the
inﬂammatory reaction [21,25]. Some studies indicated that the
stimulation of either TLR3-agonist or TLR4-agonist decreases the
suppressive ability of MSCs on allogenic T cell proliferation, indi-
cating that MSC1 and MSC2 all have pro-inﬂammatory function
[14]. The inconsistence may due to the differences of MSC sources,
MSC numbers, and incubating time of TLR-agonists during the
induction period.
The proinﬂammatory capability under the stimulation of cer-
tain infectious molecules arouses potential dangers in clinical
applications of MSCs [22]. In our study, TLR3-activation had no
effect on the BAFF expression in hMSCs. However, TLR4-activation
increased BAFF expression in MSCs and blockage of TLR4 pathway
signiﬁcantly abolished TLR4-induced BAFF expression, indicating
that TLR4-primed MSC1 phenotype impacted on B cell prolifera-
tion. Our study elucidated potential mechanisms that NF-jB, JNK,
P38 MAPM signaling pathways were involved in TLR4-related BAFF
expression. Our results were consistent with previous the studies,
in which TLR4-primed MSC1 promote T lymphocyte proliferation
and produce proinﬂammatory factors [22].
In conclusion, MSCs are gaining more and more attention due to
their immune-modulating functions, such as involving in immune
suppression. However, the heterogeneity of MSCs hinders furtherlated BAFF expression. (A) The MSCs were cultured in presence of PDTC (a NF-jB
ntration of 1 lM for 30 min. The cells were then incubated with LPS for additional
as the mean ± SD, and were compared to the group treated only with LPS (⁄p < 0.05,
ted mMSCs (left), mMSCs stimulated with LPS for 4 h (middle), and mMSCs treated
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tainty during clinical treatment. Expression of proinﬂammatory
factors under certain infectious status also elucidates more
information about the immune-modulation capabilities of MSCs.
Whether the proinﬂammatory function of MSCs aggravates the
diseases needs to be further clariﬁed. In this study, we found
that TLR4-primed MSC1 enhanced BAFF expression, whereas
TLR3-primed MSC2 exerted no inﬂuence on BAFF expression. It
supports a growing evidence that a homogeneous population of
MSCs will be important to their application in stem cell-based
therapy, which should be improved by future investigations of
identiﬁcation and characterization of speciﬁc biomarkers related
to different immune modulating function in MSCs.
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